Zhejiang Bio-diamond Pharmaceutical Technology Co., Ltd.

Main objective: To study the pharmacokinetics of the test preparation fluvastatin sodium sustained-release tablets (specification: 80 mg, licensed by Zhejiang Baidai Pharmaceutical Technology Co., Ltd.) and the reference preparation fluvastatin sodium sustained-release tablets (trade name: Lescol® XL, specification: 80 mg, licensed by Novartis Pharmaceuticals Corp) in healthy adult subjects after a single oral administration under fasting and fed conditions, and to evaluate the bioequivalence of the two preparations after oral administration under fasting and fed conditions.

The main purpose is to observe the time course of blood drug concentration after a single dose of subcutaneous injection of the test preparation progesterone injection (specification: 1.112mL: 25mg, applicant: Zhejiang Baidai Pharmaceutical Technology Co., Ltd., manufacturer: Zhejiang Thermo Pharmaceutical Co., Ltd.) in healthy subjects in the fasting state, and estimate the corresponding pharmacokinetic parameters; and use the progesterone injection (trade name: Prolutex®, specification: 1.112mL: 25mg) of the license holder IBSA Farmaceutici Italia Srl as the reference preparation to conduct a formal human bioequivalence test to provide a reference for the registration and clinical application of the drug. Secondary purpose: Observe the safety of subcutaneous injection of the test preparation and the reference preparation in the fasting state of the subjects.

Main objective: To evaluate the relative bioavailability and bioequivalence of enteric-coated aspirin tablets produced by Zhejiang EMI Pharmaceutical Technology Co., Ltd. as the test preparation and enteric-coated aspirin tablets produced by Bayer S.p.A. as the reference preparation.